Avenue Therapeutics - About the company
Avenue Therapeutics is an acquired company based in New York City (United States), founded in 2015. It operates as a Neurologic disease specialty pharmaceutical company developing impactful therapies for unmet needs. Avenue Therapeutics has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 2784 active competitors, including 915 funded and 697 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, argenx and Sana Biotechnology.
Company Details
Neurologic disease specialty pharmaceutical company developing impactful therapies for unmet needs. The company is focused on the development and commercialization of therapies for the treatment of neurologic diseases. It is advancing a diverse portfolio that includes first-in-class and best-in-class programs in a high-value neurologic landscape with significant unmet patient need. The company aims to deliver impactful therapies to patients suffering from neurologic diseases. They believe their unique pipeline of innovative treatments has the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. The company is involved in pharmaceutical development, commercialization, and therapeutic innovation within the healthcare and life sciences industries.
- Website
- avenuetx.com
- Email ID
- *****@avenuetx.com
Key Metrics
Founded Year
2015
Location
New York City, United States
Stage
Acquired
Latest Funding Round
Last Known Valuation
$***** as on Jun 30, 2017
Ranked
781st among 2784 active competitors
Annual Revenue
$1M - $10M as on Dec 31, 2025
Employee Count
10 as on Sep 30, 2026
Similar Companies
Exit Details
Acquired by Cipla (Nov 13, 2018)
Legal entities associated with Avenue Therapeutics
Avenue Therapeutics is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
AVENUE THERAPEUTICS, INC. CIN: 1644963 , United States, Active | Feb 08, 2015 | $1M - $10M (As on Dec 31, 2025) | - | - |
Avenue Therapeutics's acquisition details
Avenue Therapeutics got acquired by Cipla on Nov 13, 2018.
Click here to take a look at Avenue Therapeutics's acquisition in detail
Sign up to download Avenue Therapeutics' company profile
Avenue Therapeutics's funding and investors
Avenue Therapeutics has raised funding over 2 rounds. Its first funding round was on Jan 06, 2017.
Here is the list of recent funding rounds of Avenue Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 31, 2023 | 6882589 | Post IPO | 8891981 | 9677880 | 3960053 | 9379172 |
Jan 06, 2017 | 3646086 | Conventional Debt | 3824208 | 3170836 | 4036007 | 8230026 |
View details of Avenue Therapeutics's funding rounds and investors
Avenue Therapeutics' founders and board of directors
Founder? Claim ProfileAvenue Therapeutics' employee count trend
Avenue Therapeutics has 10 employees as of Sep 26. Here is Avenue Therapeutics's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Avenue Therapeutics's Competitors and alternates
Top competitors of Avenue Therapeutics include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of Avenue Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | 75/100 | ||
3rd | Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
6th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
7th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
8th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
9th | Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
10th | Elicio 2012, Cambridge (United States), Public | Developer of vaccines for treating cancer | $47.4M | 71/100 | |
781st | Avenue Therapeutics 2015, New York City (United States), Acquired | Neurologic disease specialty pharmaceutical company developing impactful therapies for unmet needs | - | - | 42/100 |
Looking for more details on Avenue Therapeutics's competitors? Click here to see the top ones
Avenue Therapeutics's Investments and acquisitions
Avenue Therapeutics has made no investments or acquisitions yet.
Reports related to Avenue Therapeutics
Here is the latest report on Avenue Therapeutics's sector:
News related to Avenue Therapeutics
Media has covered Avenue Therapeutics for a total of 2 events in the last 1 year.
•
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome TherapeuticsGlobeNewswire•Nov 06, 2025•Avenue Therapeutics, Axsome Therapeutics, AstraZeneca
•
Allarity Therapeutics announces new CFOSeeking Alpha•Sep 13, 2024•Allarity Therapeutics, Avenue Therapeutics
•
Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire•Aug 10, 2024•Avenue Therapeutics
•
Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease)GlobeNewswire•May 16, 2024•Avenue Therapeutics
•
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsGlobeNewswire•May 15, 2024•Avenue Therapeutics
•
•
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross ProceedsGlobeNewswire•Apr 29, 2024•Avenue Therapeutics
•
Avenue Therapeutics drops 9% on 1-for-75 reverse splitSeeking Alpha•Apr 24, 2024•Avenue Therapeutics
•
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewswire•Mar 19, 2024•Avenue Therapeutics
•
Are you a Founder ?
FAQs about Avenue Therapeutics
Explore our recently published companies
- Hotels Ubud - Unfunded company
- AM Print Media - Unfunded company
- Devseller - 2026 founded, Unfunded company
- PartStop - Unfunded company
- Comettech - United States based, Unfunded company
- Onlo Beauty - Philadelphia based, Unfunded company